Osteologie 2024; 33(02): 74-79
DOI: 10.1055/a-2270-3406

Nebenwirkungen einer medikamentösen Osteoporosetherapie und Konsequenzen für die Sequenztherapie: Fokus Arzt-Patient Kommunikation

Side Effects of Osteoporosis Pharmacotherapy and Consequences for Sequential Therapy: A Focus on Doctor-Patient Communication
Friederike Thomasius
1   Frankfurter Hormon- und Osteoporosezentrum, Frankfurt, Germany
Heide Siggelkow
2   MVZ Endokrinologikum Göttingen, Endokrinologikum-Gruppe, Hamburg, Germany
3   Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Germany
Barbara Obermayer-Pietsch
4   Universitätsklinik für Innere Medizin und Universitätsklinik für Frauenheilkunde & Geburtshilfe, Medizinische Universität Graz, Graz, Austria
› Author Affiliations


Osteoporose ist in der Mehrzahl der Fälle eine chronische Erkrankung, die auf Dauer behandelt werden muss. In der Planung der Osteoporosetherapie steht aus ärztlicher Sicht die Höhe des Frakturrisikos und das Therapieziel der Frakturrisikoreduktion im Vordergrund, aus Sicht der zu Behandelnden mindestens zusätzlich das Nebenwirkungspotential von Therapieansätzen. Beides, die Aspekte der Therapieeffizienz angesichts eines bestimmten Frakturrisikos und die potentiellen Nebenwirkungen von Therapieansätzen unter Berücksichtigung der individuellen Anamnese der Patienten sind deswegen zu kommunizieren. Die potentiell schwerwiegenden Nebenwirkungen sind im Gespräch direkt zu adressieren.


In most cases, osteoporosis is a chronic disease that requires long-term treatment. When planning osteoporosis therapy, the fracture risk and fracture risk reduction are from the doctor's point of view of primary importance and, however at least from the patient's point of view, the possible side effects of the therapeutic approaches are of high importance. This means that both of these aspects- the efficacy of the treatment with regard to a specific fracture risk and the possible side effects of the therapy – must be communicated, taking into account the patient's individual medical history. The potentially serious side effects should be addressed directly during the consultation.

Publication History

Received: 15 December 2023

Accepted: 15 February 2024

Article published online:
16 May 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Literatur

  • 1 Morley J, Moayyeri A, Ali L. et al. „Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink.“. Osteoporosis International 31.3 2020; 533-545
  • 2 Kanis JA, Cooper C, Hiligsmann M. et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporosis international 2011; 22: 2565-2573
  • 3 Yap AF, Thirumoorthy T, Kwan YH. Systematic review of the barriers affecting medication adherence in older adults. Geriatrics & gerontology international 2016; 16: 1093-1101
  • 4 Ziegler DK, Mosier MC, Buenaver M, Okuyemi K. How much information about adverse effects of medication do patients want from physicians?. Archives of internal medicine 2001; 161: 706-713
  • 5 Khan AA, Morrison A, Hanley DA, Felsenberg D. et al. „Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus“. Journal of Bone and Mineral Research 2015; 30: 3-23
  • 6 Cosman F, Crittenden DB, Adachi JD. et al. Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine 2016; 375: 1532-1543
  • 7 Palla B, Anderson J, Miloro M, Moles S, Callahan N. Romosozumab-associated medication-related osteonecrosis of the jaw. Oral and Maxillofacial Surgery Cases 2023; 100318
  • 8 Deutsche Gesellschaft für Mund-Kiefer-Gesichtschirurgie DGMKG (2018): S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ) https://register.awmf.org/assets/guidelines/007-091l_S3_Antiresorptiva-assoziierte-Kiefernekrosen-AR-ONJ_2018-12; letzter Zugriff 15.01.2023
  • 9 Rogers SN. et al United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis. Br J Oral Maxillofac Surg 2015; 53 p 176-8
  • 10 Dachverband der wissenschaftlichen Osteoporsoe Fachgesellschaften DVO (2023): S3 Leitlinie zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern ab dem 50.Lebensjahr https://register.awmf.org/de/leitlinien/detail/183-001; letzter Zugriff 15.01.2024
  • 11 Black DM, Geiger EJ, Eastell R, Vittinghoff E. et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med 2020; 383: 743-753 DOI: 10.1056/NEJMoa1916525.
  • 12 Bauer DC, Black DM, Dell R. et al. Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case Cohort Study with Blinded Radiographic Review. The Journal of Clinical Endocrinology & Metabolism, dgae023. 2024
  • 13 Saag KG, Petersen J, Brandi ML. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. New England Journal of Medicine 2017; 377: 1417-1427
  • 14 Lyles KW, Colón-Emeric CS, Magaziner JS. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. New England Journal of Medicine 2007; 357: 1799-1809
  • 15 Singh NA, Quine S, Clemson LM, Williams EJ. et al. Effects of high-intensity progressive resistance training and targeted multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: a randomized controlled trial. J Am Med Dir Assoc 2012; 13: 24-30 DOI: 10.1016/j.jamda.2011.08.005.
  • 16 Kranenburg G, Bartstra JW, Weijmans M. et al. Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis 2016; 252: 106-115
  • 17 Sambrook PN, Cameron ID, Chen JS. et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporosis international 2011; 22: 2551-2556
  • 18 Black DM, Delmas PD, Eastell R. et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822
  • 19 Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009; 32: 219-228
  • 20 Thomas Wilke AntjeGroth, Sabrina Mueller MatthiasPfannkuche. et al (2013). Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. EP Europace 2013; 15 486-493
  • 21 Gilsenan A, Midkiff K, Harris D, Kellier-Steele N. et al. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. J Bone Miner Res 2021; 36: 244-251 DOI: 10.1002/jbmr.4188.
  • 22 Tsvetov G, Amitai O, Shochat T, Shimon I. et al. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?. Osteoporosis international 2020; 31: 655-665
  • 23 Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. Patient education and counseling 2006; 60: 301-312
  • 24 Orimo H, Sato M, Kimura S, Wada K, Chen X, Yoshida S. Understanding the factors associated with initiation and adherence of osteoporosis medication in Japan: an analysis of patient perceptions. Osteoporos Sarcopenia 2017; 3: 174-184
  • 25 Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B. et al. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporosis International 30 2019; 2155-2165
  • 26 McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Current medical research and opinion 2007; 23: 3137-3152